On May 29, Hengrui Medicine rose 3.01% in regular trading, trading at HKD 59.85 per share, with trading volume of HKD 204 million.

On the news front, the company announced on May 28 that its self-developed Class 1 innovative drug Luzunore Sodium Tablets (SHR4640) received approval from China's National Medical Products Administration. The product is China's first domestically developed next-generation highly selective URAT1 inhibitor, indicated for gout patients with hyperuricemia.

The market opportunity is substantial. China has approximately 180 million hyperuricemia patients and around 36 million gout patients, representing strong chronic disease demand. The competitive landscape is favorable — globally, only one similar drug (Dotinurad) is currently on the market, with global sales of approximately USD 39.34 million, leaving significant room for Hengrui to capture market share. Additionally, the company received clinical trial approval for SHR-1819 injection targeting pediatric atopic dermatitis and HRS-1635 tablets for B-cell malignancies, further enriching its innovation pipeline.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)